CORRECTED-UPDATE 1-US court overturns Insulet's $59 mln insulin-pump trade secret verdict against EOFlow

Insulet Corporation

Insulet Corporation

PODD

0.00

Corrects amount of overturned verdict in headline and paragraph 1, adds information on reduced verdict in paragraph 3

By Blake Brittain

WASHINGTON, May 28 (Reuters) - A U.S. appeals court on Thursday overturned a $59 million verdict that medical device maker Insulet PODD.O won against Korean rival EOFlow 294090.KQ for allegedly stealing trade secrets related to its insulin-pump technology.

The Washington-based U.S. Court of Appeals for the Federal Circuit reversed the verdict after finding that Insulet had waited too long to bring its lawsuit.

A federal jury in Massachusetts had determined in 2024 that EOFlow owed $452 million in damages for misappropriating Insulet trade secrets to create a competitor to Insulet's Omnipod, a wearable insulin pump for diabetes patients. A Massachusetts judge reduced the award to $59.4 million last year.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.